FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074802279> ?p ?o ?g. }

• W2074802279 endingPage "44497" @default.
• W2074802279 startingPage "44490" @default.
• W2074802279 abstract "Aberrant glycosylation is a common feature of malignant change. Changes in mucin-type O-linked glycosylation in breast cancer can result in the expression of truncated core 1-based sialylated glycans rather than the core 2-based glycans observed in normal mammary epithelium cells. This has been shown, in part, to be due to changes in the expression of glycosyltransferases, including the up-regulation of some sialyltransferases. Using the breast cancer cell line T47D, we have shown that PGE2, one of the final products of the cyclooxygenase-2 (COX-2) pathway, can induce the mRNA expression of the sialyltransferase α-2,3-sialyltransferase-3 (ST3Gal-I), resulting in increased sialyltransferase activity, demonstrated by a reduction in PNA lectin staining. Induction of COX-2 in the MDA-MB-231 breast cancer cell line also results in the increased expression of ST3Gal-I, leading to increased sialylation of the substrate of ST3Gal-I, core 1 Galβ1,3GalNAc. This effect on sialylation could be reversed by the selective COX-2 inhibitor celecoxib. The use of siRNA to knock down COX-2 and overexpression of COX-2 in MDA-MD-231 cells confirmed the involvement of COX-2 in the up-regulation of ST3Gal-I. Moreover, analysis of the expression of ST3Gal-I and COX-2 by 74 primary breast cancers showed a significant correlation between the two enzymes. COX-2 expression has been associated with a number of tumors, including breast cancer, where its expression is associated with poor prognoses. Thus, these results suggest the intriguing possibility that some of the malignant characteristics associated with COX-2 expression may be via the influence that COX-2 exerts on the glycosylation of tumor cells. Aberrant glycosylation is a common feature of malignant change. Changes in mucin-type O-linked glycosylation in breast cancer can result in the expression of truncated core 1-based sialylated glycans rather than the core 2-based glycans observed in normal mammary epithelium cells. This has been shown, in part, to be due to changes in the expression of glycosyltransferases, including the up-regulation of some sialyltransferases. Using the breast cancer cell line T47D, we have shown that PGE2, one of the final products of the cyclooxygenase-2 (COX-2) pathway, can induce the mRNA expression of the sialyltransferase α-2,3-sialyltransferase-3 (ST3Gal-I), resulting in increased sialyltransferase activity, demonstrated by a reduction in PNA lectin staining. Induction of COX-2 in the MDA-MB-231 breast cancer cell line also results in the increased expression of ST3Gal-I, leading to increased sialylation of the substrate of ST3Gal-I, core 1 Galβ1,3GalNAc. This effect on sialylation could be reversed by the selective COX-2 inhibitor celecoxib. The use of siRNA to knock down COX-2 and overexpression of COX-2 in MDA-MD-231 cells confirmed the involvement of COX-2 in the up-regulation of ST3Gal-I. Moreover, analysis of the expression of ST3Gal-I and COX-2 by 74 primary breast cancers showed a significant correlation between the two enzymes. COX-2 expression has been associated with a number of tumors, including breast cancer, where its expression is associated with poor prognoses. Thus, these results suggest the intriguing possibility that some of the malignant characteristics associated with COX-2 expression may be via the influence that COX-2 exerts on the glycosylation of tumor cells." @default.
• W2074802279 created "2016-06-24" @default.
• W2074802279 creator A5020227286 @default.
• W2074802279 creator A5038528339 @default.
• W2074802279 creator A5048326749 @default.
• W2074802279 creator A5054254122 @default.
• W2074802279 creator A5064689120 @default.
• W2074802279 date "2012-12-01" @default.
• W2074802279 modified "2023-10-11" @default.
• W2074802279 title "Cyclooxygenase-2 Enzyme Induces the Expression of the α-2,3-Sialyltransferase-3 (ST3Gal-I) in Breast Cancer" @default.
• W2074802279 cites W1585599668 @default.
• W2074802279 cites W1648593433 @default.
• W2074802279 cites W1906960897 @default.
• W2074802279 cites W1963685103 @default.
• W2074802279 cites W1973666259 @default.
• W2074802279 cites W1978571926 @default.
• W2074802279 cites W1982680133 @default.
• W2074802279 cites W1984620813 @default.
• W2074802279 cites W2008545486 @default.
• W2074802279 cites W2009164568 @default.
• W2074802279 cites W2024191848 @default.
• W2074802279 cites W2024523736 @default.
• W2074802279 cites W2027824704 @default.
• W2074802279 cites W2054488994 @default.
• W2074802279 cites W2054871625 @default.
• W2074802279 cites W2057187298 @default.
• W2074802279 cites W2069079409 @default.
• W2074802279 cites W2078342599 @default.
• W2074802279 cites W2081660311 @default.
• W2074802279 cites W2093342110 @default.
• W2074802279 cites W2104194763 @default.
• W2074802279 cites W2104667967 @default.
• W2074802279 cites W2125381755 @default.
• W2074802279 cites W2134950344 @default.
• W2074802279 cites W2137049140 @default.
• W2074802279 cites W2139715930 @default.
• W2074802279 cites W2141346620 @default.
• W2074802279 cites W2144305967 @default.
• W2074802279 cites W2144930595 @default.
• W2074802279 cites W2145149010 @default.
• W2074802279 cites W2150124728 @default.
• W2074802279 cites W2158633610 @default.
• W2074802279 cites W2159921466 @default.
• W2074802279 cites W2169532459 @default.
• W2074802279 doi "https://doi.org/10.1074/jbc.m112.425827" @default.
• W2074802279 hasPublicationYear "2012" @default.
• W2074802279 type Work @default.
• W2074802279 sameAs 2074802279 @default.
• W2074802279 citedByCount "18" @default.
• W2074802279 countsByYear W20748022792014 @default.
• W2074802279 countsByYear W20748022792015 @default.
• W2074802279 countsByYear W20748022792016 @default.
• W2074802279 countsByYear W20748022792017 @default.
• W2074802279 countsByYear W20748022792018 @default.
• W2074802279 countsByYear W20748022792020 @default.
• W2074802279 countsByYear W20748022792021 @default.
• W2074802279 countsByYear W20748022792022 @default.
• W2074802279 crossrefType "journal-article" @default.
• W2074802279 hasAuthorship W2074802279A5020227286 @default.
• W2074802279 hasAuthorship W2074802279A5038528339 @default.
• W2074802279 hasAuthorship W2074802279A5048326749 @default.
• W2074802279 hasAuthorship W2074802279A5054254122 @default.
• W2074802279 hasAuthorship W2074802279A5064689120 @default.
• W2074802279 hasBestOaLocation W20748022791 @default.
• W2074802279 hasConcept C121608353 @default.
• W2074802279 hasConcept C126322002 @default.
• W2074802279 hasConcept C179264091 @default.
• W2074802279 hasConcept C181199279 @default.
• W2074802279 hasConcept C185592680 @default.
• W2074802279 hasConcept C2777313579 @default.
• W2074802279 hasConcept C2778322149 @default.
• W2074802279 hasConcept C2779689624 @default.
• W2074802279 hasConcept C502942594 @default.
• W2074802279 hasConcept C530470458 @default.
• W2074802279 hasConcept C54355233 @default.
• W2074802279 hasConcept C55493867 @default.
• W2074802279 hasConcept C71924100 @default.
• W2074802279 hasConcept C81885089 @default.
• W2074802279 hasConcept C86803240 @default.
• W2074802279 hasConcept C96232424 @default.
• W2074802279 hasConceptScore W2074802279C121608353 @default.
• W2074802279 hasConceptScore W2074802279C126322002 @default.
• W2074802279 hasConceptScore W2074802279C179264091 @default.
• W2074802279 hasConceptScore W2074802279C181199279 @default.
• W2074802279 hasConceptScore W2074802279C185592680 @default.
• W2074802279 hasConceptScore W2074802279C2777313579 @default.
• W2074802279 hasConceptScore W2074802279C2778322149 @default.
• W2074802279 hasConceptScore W2074802279C2779689624 @default.
• W2074802279 hasConceptScore W2074802279C502942594 @default.
• W2074802279 hasConceptScore W2074802279C530470458 @default.
• W2074802279 hasConceptScore W2074802279C54355233 @default.
• W2074802279 hasConceptScore W2074802279C55493867 @default.
• W2074802279 hasConceptScore W2074802279C71924100 @default.
• W2074802279 hasConceptScore W2074802279C81885089 @default.
• W2074802279 hasConceptScore W2074802279C86803240 @default.
• W2074802279 hasConceptScore W2074802279C96232424 @default.
• W2074802279 hasIssue "53" @default.
• W2074802279 hasLocation W20748022791 @default.

• next